<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01503840</url>
  </required_header>
  <id_info>
    <org_study_id>INT-66/11</org_study_id>
    <nct_id>NCT01503840</nct_id>
  </id_info>
  <brief_title>Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis</brief_title>
  <official_title>Evaluation of Accelerometer-Based Neuromuscular Monitoring Reliability to Exclude Postoperative Residual Paralysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <brief_summary>
    <textblock>
      Accelerometer-based neuromuscular monitoring is not the gold-standard method to evaluate
      residual postoperative paralysis but it represents the most simple, inexpensive and
      widespread tool in clinical practice. Train-of-four ratio (TOF-ratio) of 100% is considered
      the gold-standard to avoid PORC (post operative residual curarization).

      This clinical trial is conducted to verify the reliability of accelerometer-based
      neuromuscular monitoring in order to exclude postoperative residual paralysis which is not
      highlighted by this instrument at a TOF-ratio=100%.

      The study evaluates patients' neuromuscular recovery evaluated using pulmonary function tests
      after extubation at a TOFratio=100%. Administering placebo or sugammadex at a TOF ratio=100%
      allows to evaluate whether the recovery of muscle function is concrete, although the
      monitoring device shows a complete decurarization; patients treated with sugammadex should
      not be capable to perform better pulmonary function tests if a TOF ratio=100% is reliable.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      From the beginning of the surgery to the time of extubation neuromuscular block is monitored
      with accelerographic monitor TOF-Watch SX. Patients are extubated when TOF-ratio is 100%.

      Patients will perform pulmonary function tests (PFTs):

        -  the day ahead of surgery (for elegibility and training)

        -  60 minutes before surgery

        -  10 minutes after extubation

        -  5 minutes after sugammadex or placebo administration

        -  20 minutes after sugammadex or placebo administration.

      The following parameters will be evaluated and compared between the 2 groups:

        -  Maximal Inspiratory Pressure (MIP)

        -  Maximal Expiratory Pressure (MEP)

        -  Forced Expiratory Volume in the first Second (FEV1)

        -  Forced Vital Capacity (FVC)

        -  Ratio of Maximum Expiratory Flow and Maximum Inspiratory Flow rate at 50% of vital
           capacity (MEF50/MIF50)

        -  PaO2, PaCO2, pH

        -  heart rate, blood pressure and respiratory rate

      Changes of pulmonary tests performed before and after sugammadex or placebo will be compared
      between study groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Inspiratory Pressure (MIP) changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Expiratory Pressure (MEP) changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Expiratory Volume after the first second (FEV1) changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC) changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ratio of Maximum Expiratory Flow and Maximum Inspiratory Flow rate at 50% of vital capacity (MEF50/MIF50) changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemogasanalysis parameters changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallow ability changes after placebo or sugammadex</measure>
    <time_frame>10 minutes after surgery and 5 minutes later</time_frame>
    <description>10 minutes after surgery and 5 minutes later (after placebo or sugammadex administration)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Postoperative Residual Paralysis</condition>
  <arm_group>
    <arm_group_label>Sugammadex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium chloride solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sugammadex</intervention_name>
    <description>sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)</description>
    <arm_group_label>Sugammadex</arm_group_label>
    <other_name>Bridion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium chloride solution</intervention_name>
    <description>Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.</description>
    <arm_group_label>Sodium chloride solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing major abdominal surgery

          -  age between 18 and 70 years

          -  ASA class 1 or 2

          -  patients scheduled for blended anesthesia (epidural + general anesthesia)

          -  patients capable to perform pulmonary function tests (preoperative values of MIP, MEP,
             FEV1% and FEV1/FVC in normal ranges).

        Exclusion Criteria:

          -  known or suspected respiratory, cardiovascular or neuromuscular disease

          -  renal or hepatic failure

          -  known or suspected allergies to drugs used in the study

          -  risk for malignant hyperthermia

          -  pregnancy

          -  diagnosed depressive disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Federico Piccioni, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori - Milan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Piccioni F, Mariani L, Bogno L, Rivetti I, Tramontano GT, Carbonara M, Ammatuna M, Langer M. An acceleromyographic train-of-four ratio of 1.0 reliably excludes respiratory muscle weakness after major abdominal surgery: a randomized double-blind study. Can J Anaesth. 2014 Jul;61(7):641-9. doi: 10.1007/s12630-014-0160-7. Epub 2014 Apr 17.</citation>
    <PMID>24740312</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2011</study_first_submitted>
  <study_first_submitted_qc>December 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2012</study_first_posted>
  <last_update_submitted>April 20, 2014</last_update_submitted>
  <last_update_submitted_qc>April 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</investigator_affiliation>
    <investigator_full_name>Federico Piccioni, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

